P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX7728 Alone and in Combination With QPX2014 in Healthy Adult Subjects
Sponsor: Biomedical Advanced Research and Development Authority
This PHASE1 trial investigates Bacterial Infections and is currently completed. Biomedical Advanced Research and Development Authority leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE1
-
May 2022 — Sep 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Mar 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Apr 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Advanced Research and Development Authority
- Qpex Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .